Xenofon Baraliakos takes us through SURPASS, a phase 3b head-to-head trial that demonstrated equivalence of secukinumab versus adalimumab biosimilar in patients with radiographic axial spondyloarthritis.

Researchers have found that secukinumab performs equally well to adalimumab biosimilar for the treatment of radiographic axial spondyloarthritis in a head-to-head trial.

Secukinumab can be given as monotherapy or in combination with methotrexate.

Treatment with secukinumab improves outcomes for people with nonradiographic axial spondyloarthritis across different subgroups, but those with objective signs of inflammation may experience the greatest benefits, suggests a post-hoc analysis of the PREVENT trial.

In the head-to-head EXCEED trial, secukinumab did not quite attain statistical significance for superiority versus adalimumab in the joint domain.

Children and adolescents with juvenile psoriatic arthritis or enthesitis-related arthritis may benefit from treatment with the IL-17A inhibitor secukinumab, indicate phase 3 study results.

Researchers report that secukinumab is associated with an increased risk for gastrointestinal-related adverse events in patients with ankylosing spondylitis and pre-existing inflammatory bowel disease and say that prescribing alternatives should be considered.

Denis Poddubnyy reports on the spinal pain improvements seen with secukinumab in patients with axial spondyloarthritis, including the benefit of up-titration for suboptimal responders (5:16).

Denis Poddubnyy reports on the spinal pain improvements seen with secukinumab in patients with axial spondyloarthritis, including the benefit of up-titration for suboptimal responders.

Secukinumab significantly reduces spinal pain in patients with axial spondyloarthritis, with benefits seen after just 8 weeks, findings from the SKIPPAIN trial show.

Phase 3 trial results suggest that secukinumab treatment reduces synovitis among biologic-naïve patients with psoriatic arthritis and an inadequate response to conventional DMARDs.

Secukinumab significantly reduces spinal pain in patients with axial spondyloarthritis, with benefits seen after just 8 weeks, findings from the SKIPPAIN trial show.

Phase 3 trial results suggest that secukinumab treatment reduces synovitis among biologic-naïve patients with psoriatic arthritis and an inadequate response to conventional DMARDs.

Women with psoriatic arthritis may gain greater improvement in disease outcomes with secukinumab than with adalimumab, a post-hoc analysis of the EXCEED trial shows.

Latent tuberculosis infection is uncommon among people receiving secukinumab for psoriasis, psoriatic arthritis, or ankylosing spondylitis, shows a pooled analysis of clinical trial data.

The IL-17A inhibitor secukinumab may improve pain and disease activity among patients with psoriatic arthritis or axial spondyloarthritis and imaging-confirmed enthesitis at the Achilles tendon, suggest findings from the ACHILLES trial.

The IL-17A inhibitor secukinumab may improve pain and disease activity among patients with psoriatic arthritis or axial spondyloarthritis and imaging-confirmed enthesitis at the Achilles tendon, suggest findings from the ACHILLES trial.

Secukinumab shows comparable drug retention and efficacy to tumor necrosis factor inhibitors for the treatment of patients with axial spondyloarthritis and prior exposure to TNF inhibitors, observational study findings indicate.

The IL-17A inhibitor secukinumab provides significant and sustained improvements in patients with nonradiographic axial spondyloarthritis, indicate 52-week data from the phase 3 PREVENT study.

The PREVENT investigators have reported positive results for the IL-17A inhibitor secukinumab in patients with nonradiographic axial spondyloarthritis at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA.